



Please note: The Cancer Research Institute will not modify the terms of its policies at the request of individual institutions. Policies have been approved by our Board of Trustees, and we do not have the resources to negotiate separately with the many institutions that receive our support.

Upon activation of this grant, the applicant organization becomes a grantee and assumes legal and financial accountability for the awarded funds and for the performance of the grant-supported activities.

### **Financial**

- Payments will be made quarterly to the sponsoring institution. Unexpended funds may be carried over from one year to the next. Any remaining balance at the end of the grant must be returned to the Cancer Research Institute (CRI) within 30 days of termination of the award, unless an extension request is requested and granted.
- Deductions for administrative overhead or indirect costs of any kind are not permitted.
- Selected projects that meet their 12 and 24 month milestones may be eligible for follow-on funding that will enable the established proof-of-concept technology to be developed into a methodology that improves cancer immunotherapy research worldwide.

### **Progress Reports and Reports of Expenditures**

- Detailed progress reports must be submitted annually. Continued funding is contingent upon satisfactory review of annual progress reports. A comprehensive final progress report must be submitted at the end of the funding period. Progress reports are submitted online through the Cancer Research Institute's grant portal ([http://www.grantrequest.com/SID\\_2015](http://www.grantrequest.com/SID_2015)) using the login you created when submitting your application. After logging in, click Requirements and select the relevant progress report.

The reports must include:

- A 2- to 3-page summary of the research performed during the award year outlining research results;
  - A 1-page summary written in nontechnical language that points out the implications of the findings to date and their potential clinical relevance;
  - A bibliography of publications from the award year. PDF copies of publications must be attached as an addendum;
  - A list of any conferences attended and presentations given during the award year;
  - A list of any new awards or honors received;
  - An updated *curriculum vitae*;
  - A completed intellectual property disclosure form.
- The institution must submit annual expenditure reports detailing the usage of the awarded funds during the previous 12 months. Expenditures are to be reported in direct comparison to the budget provided in the original application form. Reports should also provide an explanation for any projected changes to the budget going forward. Fund balances may be carried over into the next award year, but any balance remaining at the end of the entire support period must be returned to CRI unless an administrative extension has been requested and approved. Expenditure reports should be emailed to [grants@cancerresearch.org](mailto:grants@cancerresearch.org).

### **Public Access, Publications and Acknowledgement**

- Cancer Research Institute funds biomedical research in order to better understand the causes of cancer and to advance its prevention, diagnosis and treatment. The main output of this research is new knowledge. To ensure this knowledge can be accessed, read, applied, and built upon in fulfillment of our goals, CRI expects its researchers to disseminate their findings, including publishing in peer-reviewed journals.

In addition, it is a condition of CRI funding that all peer-reviewed articles supported in whole or in part by its grants must be made available in the PubMed Central online archive. PubMed Central is a database of full-text biomedical journal articles available online without a fee, hosted by the National Library of Medicine in the National Institutes of Health. Once posted in PubMed Central, results of research become more accessible, prominent, and integrated, making it easier for scientists worldwide to pursue biomedical research. It also makes this information accessible to CRI and its donors, as well as patients, clinicians, educators, students and others.

CRI award recipients are required to deposit an electronic copy of their final peer-reviewed manuscripts in PubMed Central immediately upon acceptance for journal publication and take the steps necessary to link that manuscript to the appropriate CRI grant. The manuscript is to be made publicly available in PubMed Central no later than 12 months after the official date of journal publication. This requirement applies to all CRI grants awarded after October 1, 2017.

CRI is part of the Health Research Alliance (HRA), a national consortium of non-governmental, not-for-profit funders of biomedical research and training. HRA has made arrangements so that PubMed Central will accept deposits of manuscripts and publications resulting from research funded by HRA member organizations. All CRI award recipients are required to create an account with HRA through its Public Access Initiative. Someone from our awards team will be contacting you with information on how to create your HRA account.

- Reprints or preprints of all articles describing research supported by this grant must be submitted by the Principal Investigator. They may accompany the progress reports or be sent when available. Advance notice of any publications via email to [grants@cancerresearch.org](mailto:grants@cancerresearch.org) is appreciated. Please be sure to properly acknowledge the Cancer Research Institute in all publications (including abstracts of presentations at scientific or clinical meetings) resulting from research supported by the Institute. In addition, please be sure to acknowledge CRI in any slides you present at meetings or in any other vehicle where you are acknowledging the funds you receive to support your research. The following acknowledgment should be included: "Name of Awardee is supported by a **Cancer Research Institute Technology Impact Award (CRI Award #)**." You will receive a digital copy of the Cancer Research Institute's logo which may be inserted into presentations when appropriate.

### **Invention Policy**

- The Cancer Research Institute ("CRI") encourages the rapid development and commercialization of promising new biomedical technologies for the public benefit. In furtherance of CRI's mission of supporting high quality research in basic and tumor immunology, CRI requires that Net Income derived from any Invention be shared with CRI in accordance with this policy.

"Invention" means any invention, discovery, improvement, modification, work of authorship (excluding journal articles, textbooks or chapters of textbooks) or other work product, whether patentable or not, that is conceived, created, developed, validated or reduced to practice as a result of any research funded in whole or in part by CRI, or which is deemed to be a "work for hire" within the meaning of the U.S. Copyright Act and of which the grantee institution is deemed an author or co-author.

Unless otherwise agreed, title to an Invention shall reside with the grantee institution pursuant to the grantee institution's intellectual property ownership and licensing policies. The grantee institution agrees to use diligent efforts in obtaining patent and/or copyright protection, as applicable, and in commercializing the Invention. CRI, the grantee institution and the researcher will enter into a revenue sharing agreement in substantially the form of CRI's standard form of revenue sharing agreement, in a timely fashion prior to generation of Net Income from any Invention.

CRI's share of Net Income from an Invention shall be based on the proportionate amount of direct costs paid by CRI, the grantee institution and other funders, if any, to the research that resulted in the Invention. The first \$250,000 of Net Income will not be subject to CRI's share. "Net Income" is defined as income or other consideration resulting from the licensing, assignment or other commercialization of the Invention, less (a) any out-of-pocket expenses of the grantee institution (or the researcher, as the case may be) related to securing intellectual property protection for and commercialization of the Invention, and (b) distributions payable to inventors of the Invention (other than amounts paid as salary or other compensation or stipend support included as direct costs).

Upon the completion of each award year, and on the first anniversary of the last day of the final award year, the grantee institution, the researcher and, where applicable, the sponsor, shall complete and submit to CRI CRI's standard Intellectual Property Disclosure Form to indicate whether any Invention was developed in the performance of the relevant CRI-funded research. If an Invention was so developed, the grantee institution shall thereafter complete and submit to CRI CRI's standard Intellectual Property Annual Update form to indicate the status of any patents and copyrights and applications therefore, licensing, assignment or other commercialization of the Invention, and Net Income (and related amounts owed to CRI) during the prior year. All information disclosed to CRI marked "Confidential," or, if disclosed orally, described as confidential and promptly confirmed in writing by the grantee institution to be of a confidential nature, will be held in strict confidence and will not be disclosed to any third party without the prior written consent of the grantee institution.

---